Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.

Al-Chalabi, Ammar; Shaw, Pamela; Leigh, P Nigel; van den Berg, Leonard; Hardiman, Orla; Ludolph, Albert; Aho, Valtteri V; Sarapohja, Toni; Kuoppamäki, Mikko

Al-Chalabi, Ammar; Shaw, Pamela; Leigh, P Nigel; van den Berg, Leonard; Hardiman, Orla; Ludolph, Albert; Aho, Valtteri V; Sarapohja, Toni; Kuoppamäki, Mikko.

Afiliación

Al-Chalabi A; Department of Basic and Clinical Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.
Shaw P; Department of Neurology, King's College Hospital, London, UK.
Leigh PN; Sheffield Institute for Translational Neuroscience and NIHR Sheffield Biomedical Research Centre, University of Sheffield, Sheffield, UK.
van den Berg L; Department of Neuroscience Brighton and Sussex Medical School, Trafford Centre for Biomedical Science, Falmer, Brighton, UK.
Hardiman O; Departmentof Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.
Ludolph A; Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Aho VV; Department of Neurology, University of Ulm, Ulm, Germany.
Sarapohja T; Orion Pharma, Orion Corporation, Turku, Finland valtteri.aho@orionpharma.com.
Kuoppamäki M; Orion Pharma, Orion Corporation, Espoo, Finland.

J Neurol Neurosurg Psychiatry ; 90(10): 1165-1170, 2019 10.

Article en En | MEDLINE | ID: mdl-31315908

Asunto(s)

Esclerosis Amiotrófica Lateral/tratamiento farmacológico; Inhibidores de Fosfodiesterasa 3/uso terapéutico; Simendán/uso terapéutico; Capacidad Vital/fisiología; Adulto; Anciano; Esclerosis Amiotrófica Lateral/fisiopatología; Estudios Cruzados; Método Doble Ciego; Femenino; Humanos; Masculino; Persona de Mediana Edad; Resultado del Tratamiento

Palabras clave

SVC; amyotrophic lateral sclerosis; levosimendan; respiratory function

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Capacidad Vital / Inhibidores de Fosfodiesterasa 3 / Simendán / Esclerosis Amiotrófica Lateral Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google